Loading
Depatuxizumab mafodotin carried a cell-killing payload to glioblastomas with extra copies of the EGFR gene. It caused serious eye problems and, in the phase 3 INTELLANCE-1 trial, did not help patients live longer, so development stopped in 2019.
Depatuxizumab mafodotin (ABT-414) was AbbVie's antibody-drug conjugate for EGFR-amplified glioblastoma, present in roughly 40 to 50 percent of cases. The antibody binds EGFR only where it is overexpressed or mutated, sparing normal tissue, and delivers monomethyl auristatin F. It was given intravenously every two weeks with radiotherapy and temozolomide.
INTELLANCE-1 (RTOG 3508), a phase 3 trial in newly diagnosed EGFR-amplified glioblastoma, found no improvement in overall survival at its 2019 interim analysis and enrolment stopped; INTELLANCE-2, in recurrent disease, showed only a late trend. Corneal toxicity with blurred vision affected most patients. The glioblastoma page lists it among the major systemic trials that failed after temozolomide.
An antibody that binds a conformational EGFR epitope exposed on tumours with EGFR amplification or the EGFRvIII mutant, linked to the microtubule toxin monomethyl auristatin F; the conjugate is internalised and the payload stops cell division. Connects to EGFR and Tubulin (microtubules).
1.Depatuxizumab mafodotin's antibody arm binds EGFR on the surface of the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Depatuxizumab mafodotin" OR ABSTRACT:"Depatuxizumab mafodotin" OR TITLE:"ABT-414" OR ABSTRACT:"ABT-414" OR TITLE:"Depatux-M" OR ABSTRACT:"Depatux-M") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Depatuxizumab mafodotin, not a curated reading list.
Shares Glioma & glioblastoma and the tag subtype-drugs-wave.
Shares Antibody-drug conjugate (ADC) and the tag subtype-drugs-wave.
Shares EGFR and the tag subtype-drugs-wave.
Shares Temozolomide, Glioma & glioblastoma.
Shares Temozolomide, Glioma & glioblastoma.
Shares Temozolomide, Glioma & glioblastoma.
Shares Temozolomide, Glioma & glioblastoma.
Shares Temozolomide, Glioma & glioblastoma.